

Intermountain Precision Genomics and Asia Genomics Form Collaboration to Deliver Personalized Medicine

Genomics testing will be offered outside United States

SALT LAKE CITY, UTAH, USA, September 7, 2016 /EINPresswire.com/ -- [Intermountain Healthcare](#) and Asia Genomics have announced a collaboration for Asia Genomics to distribute a test in Southeast Asia that delivers personalized medicine. Officials from both companies finalized an agreement where Asia Genomics now contracts with Intermountain Precision Genomics to offer ICG100™ testing. Intermountain Precision Genomics ICG100™ test is Next Generation Sequencing (NGS) that identifies mutations within a person's cancer to identify specific DNA targets for personalized drug treatments. Currently approved for late stage cancer patients who have failed a traditional treatment method, the ICG100™ test offers new hope where traditional treatments fall short.

Asia Genomics has been offering various types of genomic tests in the healthcare environment since 2014. The primary focus of the tests Asia Genomics offers center on reproductive health and cancer care. "We are excited to be the first value-adding partner with Intermountain Precision Genomics outside of the U.S. Leveraging Intermountain Precision Genomics' years of experience in cancer research, diagnosis and treatment, we aim to improve survival and quality of life for cancer patients in Asia", said Dr. Wong Mun-Yew, CEO & Founder of Asia Genomics. "With this partnership, Asia Genomic continues to stay on the forefront of clinical genomics in Southeast Asia, offering the widest range of curated genomics tests and services."

"We are pleased to partner with Asia Genomics to help extend life and improve quality of life for late-stage cancer patients across Southeast Asia," said Terri Kane, Vice President of Intermountain Healthcare's Southwest Region, which includes Intermountain Precision Genomics. "Targeted therapies are the most effective treatment for late-stage cancer patients and we look forward to this partnership positively impacting the way patients receive care around the world."

Intermountain Precision Genomics is a service of Intermountain Healthcare, which offers genetic sequencing of solid tumors. This in-depth sequencing identifies individual mutations within a person's cancer cells to identify specific DNA targets for personalized drugs. For more information about Intermountain Precision Genomics please visit: [precisioncancer.org](#), join the dialog on Facebook (Intermountain Precision Genomics) or follow @precisioncancer on Twitter.

Asia Genomics specializes in clinical genomic and genetic testing. Their goal is to provide tests that have a real impact on clinical decision-making and improve health. Asia Genomics offers tests that are evidence-based, accepted and endorsed by doctors internationally. Based in Singapore, with operations in Malaysia, Philippines, Vietnam, and Thailand, Asia Genomics has a total market reach of 600,000,000 people. A venture-backed start-up, Asia Genomics plans to expand into Indonesia later this year. Visit [www.asia-genomics.com](#), on Facebook or follow @asiagenomics on Twitter.

Daron Cowley

Intermountain Healthcare
801-442-2834
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.